Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest. (2022). SKIN The Journal of Cutaneous Medicine, 6(6), s79. https://doi.org/10.25251/skin.6.supp.79